11/7/2013 8:40:37 AM
Sequenta, Inc., and its collaborators from academic institutions around the world will share data demonstrating the validity and prognostic value of the ClonoSIGHT test for minimal residual disease (MRD) in four oral and 13 poster presentations, encompassing eight different blood cancer subtypes, at the annual meeting of the American Society of Hematology (ASH) being held December 7-10, 2013 in New Orleans, La.
Help employers find you! Check out all the jobs and post your resume.
comments powered by